GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clal Biotechnology Industries Ltd (XTAE:CBI) » Definitions » Liabilities-to-Assets

Clal Biotechnology Industries (XTAE:CBI) Liabilities-to-Assets : 0.23 (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Clal Biotechnology Industries Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Clal Biotechnology Industries's Total Liabilities for the quarter that ended in Dec. 2023 was ₪36.98 Mil. Clal Biotechnology Industries's Total Assets for the quarter that ended in Dec. 2023 was ₪158.39 Mil. Therefore, Clal Biotechnology Industries's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2023 was 0.23.


Clal Biotechnology Industries Liabilities-to-Assets Historical Data

The historical data trend for Clal Biotechnology Industries's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clal Biotechnology Industries Liabilities-to-Assets Chart

Clal Biotechnology Industries Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Liabilities-to-Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.19 0.16 0.24 0.21 0.23

Clal Biotechnology Industries Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Dec23
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.26 0.20 0.21 0.21 0.23

Competitive Comparison of Clal Biotechnology Industries's Liabilities-to-Assets

For the Biotechnology subindustry, Clal Biotechnology Industries's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clal Biotechnology Industries's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clal Biotechnology Industries's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Clal Biotechnology Industries's Liabilities-to-Assets falls into.



Clal Biotechnology Industries Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Clal Biotechnology Industries's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Liabilities-to-Assets (A: Dec. 2023 )=Total Liabilities/Total Assets
=36.978/158.386
=0.23

Clal Biotechnology Industries's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2023 is calculated as

Liabilities-to-Assets (Q: Dec. 2023 )=Total Liabilities/Total Assets
=36.978/158.386
=0.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Clal Biotechnology Industries  (XTAE:CBI) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


Clal Biotechnology Industries Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Clal Biotechnology Industries's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Clal Biotechnology Industries (XTAE:CBI) Business Description

Traded in Other Exchanges
N/A
Address
Azrieli Center, Triangle Building, 45th Floor, Tel Aviv, ISR, 67023
Clal Biotechnology Industries Ltd is a life sciences investment company. The company invests in companies ranging from seed to maturity, both public and private. Its portfolio of investments includes from heavy industry to biotechnology, hi-tech and energy companies.

Clal Biotechnology Industries (XTAE:CBI) Headlines

From GuruFocus

CBI: Former Buffett Stock Worth Buying Now

By Jonathan Poland Jonathan Poland 06-29-2017

CB&I Announces Novolen Technology Award in China

By PRNewswire PRNewswire 04-03-2018

Arnold Van Den Berg Keeps Buying Chicago Bridge and Iron Company

By Ashish Sharma Lalitsharma 05-26-2015

CB&I Announces Preliminary First Quarter 2018 Financial Results

By PRNewswire PRNewswire 04-12-2018

McDermott Awarded Paraxylene (pX) Technology Contract in China

By PRNewswire PRNewswire 06-13-2019

Van Den Berg Almost Sells Out 4 Stakes in 1st Quarter

By David Goodloe David Goodloe 04-20-2016

Richard Snow Increases His Stake in Chicago Bridge and Iron

By Ashish Sharma Lalitsharma 09-14-2015